Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure

SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (NASDAQ:VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) in a joint briefing held on May 14, 2026. The session was Valion Bio's second engagement with senior Department of War officials, following the Company's April 28, 2026, Pentagon briefing on Entolimod.

We believe the cross-agency engagement reflects continued U.S. government interest in Entolimod as a differentiated medical countermeasure for radiological threats. Agency discussion included a specific interest in an oral formulation of the Company's lead candidate, which would offer operational advantages over injectable agents in mass-casualty scenarios and support broader field deployment for the warfighter. and national stockpile integration.